R&D
Vettiva applies scientific rigor and technical excellence in the development of innovative pharmaceutical therapies based on cannabidiol (CBD), with a focus on safety, efficacy, and clinical evidence. Since 2018, we have been conducting veterinary research grounded in our proven experience in the human healthcare sector. Our pipeline fully complies with regulatory agency requirements, encompassing preclinical studies, controlled clinical trials, and qualification of pharmaceutical-grade inputs. We leverage internationally recognized technologies to scientifically validate the therapeutic effects of CBD on clinically relevant conditions in dogs and cats.
The launch of our first innovative therapy is scheduled for late 2025. Our Research & Development portfolio includes multiple advanced-stage therapeutic candidates aimed at treating high-prevalence conditions with unmet medical needs for more effective and/or safer therapies in companion animals. All pharmaceutical development and product manufacturing take place in a U.S.-based facility certified by the FDA (Food and Drug Administration) and other international health authorities, ensuring technical and regulatory excellence throughout the entire process.
Product Pipeline
Research and development stages for the new drug:
ACCESS
Discovery of the substance
-
Biological and pathophysiological evaluation of the disease;
-
Identifies and validates targets;
-
Molecule tracking;
-
Laboratory tests.
PRE-CLINICAL PHASE
In vitro and in vivo tests
-
Safety and toxicity studies;
-
Initial formulation;
-
Assessment of pharmacokinetics and pharmacodynamics.
CLINICAL PHASE I
Safety dose assessment
-
Discovery of markers for safety and toxicity;
-
Determines the optimal dose to be tested;
-
Pharmacokinetic assessment.
CLINICAL PHASE II
Assessment of potential efficacy and safety
-
Measures preliminary effectiveness;
-
Investigates the occurrence of adverse effects;
-
Determines dose and dosage;
-
Inclusion and exclusion criteria.
CLINICAL PHASE III
Evaluation of efficacy and safety
-
Assessment of efficacy, safety, interactions, and contraindications in the medium term;
-
Multicenter, comparative studies;
-
Restricted inclusion and exclusion criteria.
APPROVAL BY MAP
Post-market evaluation
-
Assesses effectiveness, risks, safety and long-term benefits;
-
Allows assessment of rare side effects.
*Legal Disclaimer: Vettiva does not sell any products. All current activities of the company are exclusively within the scope of research and development of medicines. All information contained on this website is not for commercial and/or product promotional purposes.